Overview

• Novo Nordisk cut its 2025 sales growth forecast to 8%–14% and operating profit growth to 10%–16%, down sharply from prior guidance.
• Maziar Mike Doustdar will assume the CEO role on August 7, replacing Lars Fruergaard Jørgensen to lead the company’s next growth phase.
• Shares fell more than 20% in U.S. trading, wiping out over $60 billion in market value after the guidance downgrade.
• Compounded semaglutide knockoffs have continued to cannibalize Wegovy and Ozempic sales despite FDA restrictions.
• The company merged two research and development units under chief scientist Martin Holst Lange to accelerate innovation.